title: Current and emerging treatment options for myopic choroidal neovascularization.
abstract: Choroidal neovascularization (CNV) is the main cause of visual impairment in highly myopic patients younger than 50 years of age. There are different treatments for myopic CNV (mCNV), with 5- to 10-year outcomes currently. Chorioretinal atrophy is still the most important determinant factor for visual outcome. The purpose of this study is to provide an overview of the current treatments for mCNV, including laser, surgical management, verteporfin photodynamic therapy, and mainly anti-vascular endothelial growth factor therapy. Emerging treatment options are also discussed.
authors.affiliation: Department B of Ophthalmology, Hedi Rais Institute of Ophthalmology, Faculty of Medicine of Tunis, University of El Manar, Tunis, Tunisia.
authors.forename: Leila
authors.initials: L
authors.lastname: El Matri
authors.affiliation: Department B of Ophthalmology, Hedi Rais Institute of Ophthalmology, Faculty of Medicine of Tunis, University of El Manar, Tunis, Tunisia.
authors.forename: Ahmed
authors.initials: A
authors.lastname: Chebil
authors.affiliation: Department B of Ophthalmology, Hedi Rais Institute of Ophthalmology, Faculty of Medicine of Tunis, University of El Manar, Tunis, Tunisia.
authors.forename: Fedra
authors.initials: F
authors.lastname: Kort
keywords: choroidal neovascularization; current treatment; emerging treatment; myopia